Al­ler­gy Ther­a­peu­tic­s' im­munother­a­py prospect tar­nished af­ter birch vac­cine flops in PhI­II

When the FDA lift­ed a 5-year clin­i­cal hold on Al­ler­gy Ther­a­peu­tics’ grass pollen al­ler­gy vac­cine, CEO Manuel Llo­bet sig­naled that the com­pa­ny need­ed on­ly to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER